Eli Lilly seems to have responded to the threat by President Donald Trump of tariffs on the pharma industry if they don't relocate their manufacturing operations to the US. The pharma group has ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

Other companies, domestic and foreign, have recently warned customers that price hikes related to tariffs are on the way.